GLP-1受体激动剂通过调节肠道微生物群和3组先天性淋巴细胞的功能来缓解结肠炎症
Hanxiao Sun1,2, Jie Shu2, Jupei Tang3
1Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, China.
Immunology
|March 28, 2024
概括
类似葡萄糖-1受体激动剂 (GLP-1RAs) 治疗2型糖尿病,并可能通过促进有益的肠道细菌和IL-22-产生先天性淋巴细胞 (ILC3s) 来帮助炎症性肠病 (IBD). 这项研究揭示了IBD治疗的潜在微生物群-DMS-IL-22+ILC3轴.
科学领域:
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
- 微生物学 微生物学
背景情况:
- 类似葡萄糖类-1受体激动剂 (GLP-1RAs) 用于2型糖尿病.
- GLP-1RAs在炎症性肠病 (IBD) 中显示出潜在的抗炎作用.
- 目前尚不完全了解GLP-1RA对IBD影响的确切机制.
研究的目的:
- 研究GLP-1RAs在硫酸 (DSS) 诱导的大肠炎中的治疗机制.
- 阐明3组先天性淋巴细胞 (ILC3s) 在GLP-1RA介导的对大肠炎的保护中的作用.
- 探索肠道微生物群和代谢物在GLP-1RA治疗大肠炎中的影响.
主要方法:
- 利用硫酸 (DSS) 诱导的大肠炎小鼠模型,包括野生型,T/B细胞缺乏和ILC3缺乏的小鼠.
- 评估了GLP-1RAs对IL-22由ILC3s产生的影响.
- 分析了肠道微生物群组成和便代谢物,使用16S rRNA测序和GC/LC-MS.
- 研究了N,N-二甲基斯芬戈辛 (DMS) 在结肠炎和ILC3功能中的作用.
主要成果:
- 在小鼠中,GLP-1RAs通过调节3组先天性淋巴细胞 (ILC3) 来改善DSS诱导的大肠炎.
- GLP-1RAs促进了ILC3s的IL-22产生,这是它们保护作用的关键因素.
- GLP-1RAs的治疗益处取决于肠道微生物群,这些微生物群被改变以有利于有益的细菌,如Lactobacillus reuteri.
- 在接受GLP-1RA治疗的小鼠中,一种内源代谢物N,N-二甲基辛 (DMS) 得到了丰富,并显示出大肠炎改善和ILC3促进的特性.
结论:
- GLP-1RAs通过调节肠道微生物群-DMS-IL-22+ILC3轴,对大肠炎产生治疗作用.
- 这项研究强调了GLP-1RAs作为治疗炎症性肠道疾病的治疗策略的潜力,特别是那些患有糖尿病并发症的人.
- 向微生物群-DMS-IL-22+ILC3通路可能为IBD提供新的治疗途径.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
162
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
162
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Drugs for Treatment of Diarrhea-Predominant IBS
166
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
166
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
252
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
252
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Renewal of Intestinal Stem Cells
2.6K
The intestinal epithelial lining rapidly renews every 4 to 5 days. The renewal is facilitated by intestinal stem cells (ISCs) located at the base of the crypt– a gland located at the bottom of each villus. ISCs divide asymmetrically to form new stem cells and progenitor daughter cells. The daughter cells are called transit-amplifying (TA) cells which move upwards along the crypt and either differentiate into absorptive cells– the enterocytes or secretory cells– including the...
2.6K


